US Markets
Home›US Markets›Sectors›Pill-form peptide drugs emerge as a target for big pha…
Pill-form peptide drugs emerge as a target for big pharma profits
The WSJ Markets notes pill-form peptides may be positioned to compete with big pharma’s most profitable franchises.
WSJ Markets says the current peptide growth wave is less about muscle-building use cases and more about pill-form peptides.
The outlet frames pill-form peptide drugs as a potential major opportunity for big pharma.
In particular, WSJ Markets points to the possibility that these oral peptides could be aimed at big pharma’s most profitable drug franchises.
← Newer storyRising interest rates spark renewed concerns about the economyOlder story →Oracle issues force majeure notice tied to Project Jupiter build-out